Cadila Healthcare announced that the manufacturing facility of Zydus Hopsira Oncology, a 50:50 joint venture company between Zydus Cadila and Hospira Inc., USA (now part of Pfizer Group) at Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA which concluded that the inspection is "closed" and states that the
inspection classification of this facility is 'Voluntary Action Indicated' (VAI). The manufacturing plant had completed the USFDA audit from 5 to 12 April, 2018.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
